11th April 2022 | Pharma Updates
Due to vial contamination, Moderna is recalling 764,900 doses of Covid vaccine
Moderna announced the recall of 764,900 doses of its Covid-19 vaccine after a vial manufactured by its contract manufacturer Rovi was discovered to be contaminated with a foreign substance.
Torrent and JB Chemicals are in a competition to acquire Curatio Healthcare
Torrent Pharmaceuticals and KKRcontrolled JB Chemicals are among the final candidates to acquire Chennai-based Curatio Healthcare for over 2,500 crore in what might be a continuation of M&A deals in the pharma and life sciences space.
Two-year overall survival of 32.5% in patients with advanced NSCLC in Lumakras Codebreak 100 study
Lumakras, only licenced KRASG12C inhibitor, is a transformational targeted therapy for treatment of patients with KRAS G12C-mutated NSCLC, with thousands of patients treated.
A covaxin booster boosts antibody response against Covid variations
A booster dose of Covaxin given six months after the two-dose main vaccination showed enhanced immune responses against SARS-CoV-2 variants of concern, as per study conducted by the ICMR and Bharat Biotech.
Cadila introduces ThRabis,the world's firstthree-dose rabies vaccine
Cadila Pharmaceuticals said that it had created the world’s first novel three-dose rabies vaccine, known as ‘ThRabis, ‘ a recombinant nano-particle-based G protein vaccine created utilising Viruslike Particle technology.
Telix Pharmaceuticals Announces Olaratumab Licensing Agreement with Lilly
Telix announces the signing of a licence deal with Eli Lilly and Company to commercialise radiolabelled variants of Lilly’s olaratumab antibody for the diagnosis and treatment of human malignancies.
Current COVID vaccines, according to the FDA, are ineffective against the new strain
FDA experts stated unequivocally that there is much they do not know; that present vaccines are not well-matched to the current sub-variant BA.2, and that future sub-variants will likely align with current vaccines even less.
